A detailed history of Rhumbline Advisers transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Rhumbline Advisers holds 303 shares of CALT stock, worth $12,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
303
Previous 202 50.0%
Holding current value
$12,120
Previous $7,000 71.43%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$38.0 - $41.55 $3,838 - $4,196
101 Added 50.0%
303 $12,000
Q2 2024

Aug 01, 2024

BUY
$17.65 - $41.41 $670 - $1,573
38 Added 23.17%
202 $7,000
Q4 2023

Feb 08, 2024

BUY
$15.79 - $28.99 $236 - $434
15 Added 10.07%
164 $4,000
Q3 2023

Nov 09, 2023

BUY
$15.68 - $20.38 $156 - $203
10 Added 7.19%
149 $2,000
Q2 2023

Aug 08, 2023

BUY
$15.7 - $25.61 $2,182 - $3,559
139 New
139 $2,000

Others Institutions Holding CALT

About Calliditas Therapeutics AB


  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.06B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.